SRR8518303
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.280
- MYC_TARGETS_V2+0.280
- OXIDATIVE_PHOSPHORYLATION+0.280
- ADIPOGENESIS+0.240
- PEROXISOME+0.230
- E2F_TARGETS+0.220
- PANCREAS_BETA_CELLS+0.220
- DNA_REPAIR+0.190
- FATTY_ACID_METABOLISM+0.190
- APICAL_SURFACE+0.150
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- TGF_BETA_SIGNALING-0.360
- WNT_BETA_CATENIN_SIGNALING-0.360
- ALLOGRAFT_REJECTION-0.350
- IL6_JAK_STAT3_SIGNALING-0.330
- UV_RESPONSE_DN-0.330
- COMPLEMENT-0.320
- KRAS_SIGNALING_UP-0.310
- HEDGEHOG_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20070010.LumB | — | B | 0.800 |
| 2 | SRR26320088 | — | — | 0.800 |
| 3 | 20120289.LumB | — | B | 0.793 |
| 4 | TCGA-A7-A4SF-01A-11R-A266-07 | — | B | 0.792 |
| 5 | bc467b80-495a-43d8-837a-4385aa178307 | — | — | 0.791 |
| 6 | MNG563 | — | — | 0.790 |
| 7 | TCGA-CQ-A4C9-01A-11R-A24Z-07 | — | — | 0.789 |
| 8 | TCGA-GV-A40G-01A-11R-A23N-07 | — | — | 0.788 |
| 9 | ERR2208933 | — | — | 0.781 |
| 10 | TCGA-CN-A63U-01A-11R-A30B-07 | — | — | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |